Beacon Therapeutics

Gene therapy offers hope by repairing genetic flaws, enhancing the body's natural healing abilities, and improving the quality of life.

Beacon Therapeutics reports completed clinical trials for laru-zova (AGTC-501) in XLRP, including phases 1/2 (HORIZON) and phase 2 (SKYLINE).

Beacon Therapeutics targets CDHR1 gene mutations to address cone rod dystrophy (CRD) and inherited eye disorders.

Beacon Therapeutics conducts clinical trials for gene therapy but does not offer expanded access for laru-zova (AGTC-501).

Beacon Therapeutics presents interim and phase 2 trial results for laru-zova (AGTC-501) in XLRP and X-linked retinitis pigmentosa.

Beacon Therapeutics Launch: Pioneering ophthalmic gene therapy with £96M funding for groundbreaking treatments targeting retinal diseases and blindness.

The Associate Director, Data Management will be responsible for leading the data management processes for all clinical studies at the Company. Apply now!

Beacon Therapeutics offers career opportunities in gene therapy to advance vision restoration.

Lead as Director/Sr. Dir/Ex Dir in Clinical Development, Drug Safety, and Pharmacovigilance Physician. Ophthalmology expertise preferred. Remote, East Coast, USA.

Beacon Therapeutics provides job openings in pioneering gene therapy research.

Chris Hollowood, PhD is the Chairman of the Beacon Board of Directors.

Dmitrij Hristodorov is General Partner at Forbion, a leading European life sciences venture capital firm.

Duncan Whitaker: SVP, Head of IP and Legal with 20 years' expertise in life science IP. Former leader at Freeline and key contributor to biotech success stories.

Eduardo Jacobo: SVP of Technical Operations with 30+ years in GMP. Formerly SVP at Sangamo Therapeutics; leadership at Eli Lilly, Amgen, Zimmer & Ametek.

Beacon Therapeutics develops ocular gene therapy to restore vision in patients.

100 CambridgePark Drive, Suite 2200
 Cambridge, MA 02140, US

Beacon Therapeutics uses ophthalmic gene therapy to restore and improve patient vision.

Beacon Therapeutics outlines privacy safeguards and data protection policies.

Beacon Therapeutics announces positive topline results from its pivotal VISTA trial assessing laru-zova (laruparetigene zovaparvovec) for treating X-linked retinitis pigmentosa (XLRP). The trial supports registration efforts for the gene therapy candidate targeting rare ocular diseases. Beacon focuses on restoring vision in patients with rare and prevalent eye conditions.

Sep 2026Beacon TherapeuticsNews article

Beacon Therapeutics secures over **$75 million** in an oversubscribed **Series C** funding round, led by **Goldman Sachs Alternatives** and supported by the **Retinal Degeneration Fund (RD Fund)**. The company, focused on **ocular disease treatments**, advances its clinical-stage pipeline targeting rare and common vision disorders. Investors include both new and existing backers, reflecting strong demand for its therapeutic programs.

Jan 2026Beacon TherapeuticsNews article

Beacon Therapeutics initiates the LANDSCAPE trial, administering laru-zova bilaterally to the first patient with X-linked retinitis pigmentosa (XLRP). The open-label study evaluates the safety of the treatment in affected individuals. This marks a key step in assessing laru-zova’s potential for patients suffering from this inherited retinal disease.

Dec 2025Beacon TherapeuticsNews article

Beacon Therapeutics secures FDA **Regenerative Medicine Advanced Therapy (RMAT)** designation for its gene therapy **laru-zova (laruparetigene zovaparvovec)** targeting **X-linked retinitis pigmentosa (XLRP)**. The company specializes in ophthalmic gene therapies to treat blinding retinal diseases. RMAT status accelerates development and review for innovative regenerative treatments.

Jan 2025Beacon TherapeuticsNews article